Paronychia associated with antiretroviral therapy.
We report six HIV patients who developed painful periungual inflammation of several nails during treatment with the antiretroviral drugs indinavir and lamivudine. The lesions appeared 2-12 months after starting treatment. The occurrence of paronychia in HIV patients has recently been reported in two groups of patients receiving either indinavir or lamivudine. Dermatologists should be aware of this recently reported and probably not uncommon side-effect of antiretroviral treatment in order to avoid an invasive approach to the nail lesions.
Tosti
A
A
Department of Dermatology, University of Bologna, Via Massarenti 1, I-40138 Bologna, Italy. tosti@almadns.unibo.it
Piraccini
B M
BM
D'Antuono
A
A
Marzaduri
S
S
Bettoli
V
V
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002990:Clobetasol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005938:Glucocorticoids; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D019259:Lamivudine / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D016712:Mupirocin / Q000627:therapeutic use; D010304:Paronychia / Q000139:chemically induced* / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D019259:Lamivudine; D019469:Indinavir; D002990:Clobetasol; D016712:Mupirocin